Physicians' Academy for Cardiovascular Education

Novel PCSK9 outcomes in perspective: Lessons from FOURIER & ODYSSEY

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Jennifer Robinson, MD - Iowa city, Iowa, USA - Online CME

Prof. Jennifer Robinson illustrates the importance of baseline LDL-c levels in CV risk reduction with PCSK9 inhibitors and explains which patients should get this treatment.

Video navigation menu

  • Baseline LDL-c drives endpoints for CV risk 02:22
  • More CV benefit with PCSK9 inhibitors at higher baseline LDL-c levels 05:15
  • Clinical guidance: categorizing patients for risk 07:55
  • Clinical guidance: phenotyping patients 09:51
  • Clinical guidance: cost effectiveness 10:36

Educational information

This lecture by prof. Jennifer Robinson was part of a CME accredited symposium: "PCSK9 inhibition: Science, outcomes and guidance" held at ESC 2018 in Munich, Germany.


Prof. Jennifer Robinson, MD - Iowa city, Iowa, USA


This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-cme.


Funding for this educational program was provided by unrestricted educational grants from Amgen and Sanofi-Regeneron.

View slides of prof. Robinson


This is available as accredited online CME for members. Click the button below to enroll:

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: